Tumour response following preoperative chemotherapy is affected by body mass index in patients with colorectal liver metastases

Table 2 Univariate regression analysis of factors for complete tumour response

Factor	n (%)	Complete tumour response (TRG1-2)
		OR (95%CI)	P value
Male	85 (67.5)	0.42 (0.18-1.02)	0.054
Age ≥ 60 yr	54 (42.9)	0.90 (0.38-2.13)	0.802
Low BMI	74 (58.7)	3.98 (1.39-11.34)	0.010
Weight gain ≥ 5%	34 (27.0)	0.68 (0.24-1.90)	0.460
Weight loss ≥ 5%	17 (13.5)	0.68 (0.18-2.63)	0.575
Hypertension	50 (39.7)	0.57 (0.23-1.43)	0.232
Diabetes	20 (15.9)	0.60 (0.16-2.23)	0.449
Primary site, colon	62 (49.2)	0.78 (0.33-1.84)	0.577
Lymph nodal metastasis1	77 (68.8)	0.88 (0.35-2.22)	0.789
Synchronous	83 (65.9)	2.09 (0.77-5.65)	0.147
Bilobar distribution	47 (37.3)	1.78 (0.75-4.20)	0.192
Diameter ≥ 3.0 cm	46 (36.5)	1.53 (0.64-3.63)	0.336
Multiple metastases	61 (48.4)	1.19 (0.51-2.79)	0.687
Oxaliplatin-based regimen	95 (75.4)	3.15 (0.88-11.32)	0.078
Bevacizumab	45 (35.7)	2.88 (1.20-6.87)	0.018
Cycles > 6	32 (25.4)	0.80 (0.29-2.21)	0.669
Preoperative CEA < 10 ng/mL	74 (58.7)	3.98 (1.39-11.34)	0.010
Steatosis	73 (57.9)	1.07 (0.45-2.55)	0.875
Sinusoidal dilatation	103 (82.4)	0.64 (0.22-1.85)	0.412
Severe steatosis (grade 2-3)	17 (13.5)	1.65 (0.53-5.17)	0.392
Severe sinusoidal dilatation (grade 2-3)	30 (23.8)	0.20 (0.05-0.91)	0.038

¹Primary tumour Lymph nodal status data was available in 112 patients. TRG: Tumour regression grade; BMI: Body mass index; CEA: Carcinoembryonic antigen; OR: Odds ratio; CI: Confidence interval.